Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study

Hiyama, Eiso; Iehara, Tomoko; Sugimoto, Tohru; Fukuzawa, Masahiro; Hayashi, Yutaka; Sasaki, Fumio; Shimada, Masahiko; Kondo, Satoshi; Yoneda, Akihiro; Yamaoka, Hiroaki; Tajiri, Tatsuro; Akazawa, Kohei; Ohtaki, Megu

doi:10.1016/s0140-6736(08)60523-1

Cited by 90 publications

(44 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain tumors are found during the prenatal diagnosis prior to delivery (22). In the present study, patients < 6 months old were all at stage 4s, which was consistent with the results of previous studies (23,24). According to the COG classification, the majority of cases were in the low-and intermediate-risk groups (9 cases), and the rest were in the high-risk group (7 cases).…”

Section: Discussionsupporting

confidence: 92%

Clinical characteristics of infant neuroblastoma and a summary of treatment outcome

et al. 2016

View full text Add to dashboard Cite

Abstract. Neuroblastoma (NB) is the most common malignant solid tumor in the peripheral nervous system in infants and young children, with a high degree of malignancy. The clinical characteristics and prognosis of NB in infants are unique. The present study retrospectively analyzed the prognosis of infant NB cases that underwent different treatments. In total, 16 infant NB cases (10 male and 6 female) who were treated between February 2007 and August 2013 in Beijing Tongren Hospital (Beijing, China), were enrolled in the study. They were diagnosed by pathology, medical imaging and serology methods. These 16 patients were subjected to comprehensive treatment, including chemotherapy, surgery, autologous peripheral blood stem cell transplantation (APBSCT) and radiation therapy. The age distribution and clinical stages were: 5 cases (31.25%) at ≤3 months (4 cases at stage 4s and 1 case at stage 4); 2 cases (12.5%) at 3-6 months (both at stage 4s); and 9 cases (56.25%) at 6-12 months (2 cases at stage 4s, 6 cases at stage 4 and 1 case at stage 3). Subsequent to treatment, nicotinic acid esterase (NSE) levels in the patient's serum significantly decreased. The NSE levels in 12 cases (75%) dropped to the reference value (0-15.2 ng/dl). All the NB infants at stages 4s and 3 were treated by surgery and chemotherapy (100%; 9/9). The 5 NB infants at stage 4 were treated by chemotherapy and surgery. For the 2 NB infants who experienced recurrence or whose condition was partially relieved after conventional therapy, APBSCT therapy was applied. At the last follow-up in September 2014, 13 cases (81.25%) presented with a complete response, 2 cases (12.50%) with a partial response and 1 case (6.25%) with recurrence after transplantation (progressive disease). In conclusion, infant NB cases are sensitive to chemotherapy, particularly the cases at stage 4s, which occur with a higher incidence, but with a better clinical response and prognosis after treatment. IntroductionNeuroblastoma (NB) is the most common malignant solid tumor from the peripheral nervous system. The disease originates from neural crest cells and accounts for 7-10% of malignant tumors among children (1-3). Several genetic abnormalities associated with NB have been characterized, including DNA content, gain of chromosome arm 17q or deletion of chromosome arms 1p and 11q (4-8). NB occurs frequently in infants, with a high degree of malignancy. According to the stage standard of the International Neuroblastoma Staging System (INSS) (9), NB is classified into stages 1-4, with a special stage 4s. Stage 4s cases occur in infants who are <1 year old. These cases are sensitive to chemotherapy, with a better prognosis than cases at stages 3 and 4. NB infants are mainly treated with surgery in conjunction with chemotherapy and radiotherapy. The response to the treatment also depends on the age of the patients and their sensitivity to chemotherapy. Previous studies have shown that the most robust prognostic factors are age, stage, histology and amplification of the N-Myc o...

show abstract

Section: Discussionsupporting

confidence: 92%

Clinical characteristics of infant neuroblastoma and a summary of treatment outcome

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Large-scale national screening studies of infants via evaluation of urinary catecholamine levels have led to the diagnosis of neuroblastoma in a higher number of children, although most of the detected tumors were low risk, with favorable clinical and biological features [6][7][8][9]. In multiple studies, screening of asymptomatic infants has not resulted in increased detection rates for advanced disease, which usually presents at an older age.…”

Section: Epidemiology and Geneticsmentioning

confidence: 99%

Overview and recent advances in the treatment of neuroblastoma

Whittle

Smith

Doherty

et al. 2017

Expert Review of Anticancer Therapy

296

232

View full text Add to dashboard Cite

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.ARTICLE HISTORY

show abstract

“…Neuroblastoma is an extracranial, heterogeneous, and malignant solid tumor of the sympathetic nervous system in children and it accounts for approximately 15% of pediatric cancer deaths in the United States [1]. The genetic features of neuroblastoma include near triploid karyotype, deletion of short arm of chromosome 1, high expression of neurotrophin receptors (TrkA and TrkB), and N-Myc amplification or allelic loss, all of which are associated with malignant transformation and progression of this disease.…”

Section: Introductionmentioning

confidence: 99%

Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification

et al. 2009

View full text Add to dashboard Cite

Neuroblastoma is an extracranial, solid, and heterogeneous malignancy in children. The conventional therapeutic modalities are mostly ineffective and thus new therapeutic strategies for malignant neuroblastoma are urgently warranted. We examined the synergistic efficacy of combination of sorafenib (SF) and genistein (GST) in human malignant neuroblastoma SK-N-DZ (N-Myc amplified) and SH-SY5Y (N-Myc non-amplified) cell lines. MTT assay showed dose-dependent decrease in cell viability and the combination therapy more prominently inhibited the cell proliferation in both cell lines than either treatment alone. Apoptosis was confirmed morphologically by Wright staining. Flow cytometric analysis of cell cycle phase distribution and Annexin V-FITC/PI staining showed increase in subG1 DNA content and early apoptosis, respectively, after treatment with the combination of drugs. Apoptosis was further confirmed by scanning electron microscopy. Combination therapy showed activation of caspase-8, cleavage of Bid to tBid, increase in p53 and p21 expression, down regulation of anti-apoptotic Mcl-1, and increase in Bax:Bcl-2 ratio to trigger apoptosis. Down regulation of MDR, hTERT, N-Myc, VEGF, FGF-2, NF-κB, p-Akt, and c-IAP2 indicated suppression of angiogenic and survival pathways. Mitochondrial release of cytochrome c and Smac into cytosol indicated involvement of mitochondia in apoptosis. Increases in proteolytic activities of calpain and caspase-3 were also confirmed. Our results suggested that combination of SF and GST inhibited angiogenic and survival factors and increased apoptosis via receptor and mitochondria mediated pathways in both neuroblastoma SK-N-DZ and SH-SY5Y cell lines. Thus, this combination of drugs could be a potential therapeutic strategy against human malignant neuroblastoma cells having N-Myc amplification or non-amplification.

show abstract

Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study

Cited by 90 publications

References 27 publications

Clinical characteristics of infant neuroblastoma and a summary of treatment outcome

Clinical characteristics of infant neuroblastoma and a summary of treatment outcome

Overview and recent advances in the treatment of neuroblastoma

Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification

Contact Info

Product

Resources

About